Anticoagulation by factor Xa inhibitors

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 8, 2010, Pages 1745-1753

  Orfeo, T ^a   Butenas, S ^a   Brummel Ziedins, K E ^a   Gissel, M ^a   Mann, K G ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Anticoagulation; Computational and empirical models; Factor Xa; Fondaparinux; Rivaroxaban; Thrombin generation

Indexed keywords

FONDAPARINUX; RIVAROXABAN; THROMBOPLASTIN; WARFARIN;

ANTICOAGULATION; ARTICLE; CATALYST; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; PRIORITY JOURNAL; PROTEIN PURIFICATION; THROMBIN TIME; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; COMPUTER SIMULATION; FACTOR V; FACTOR XA; HUMANS; MORPHOLINES; POLYSACCHARIDES; RECOMBINANT PROTEINS; SOFTWARE; THIOPHENES; THROMBIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 77958534664     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03917.x     Document Type: Article

References (31)

1. Marcum JA. The origin of the dispute over the discovery of heparin. J Hist Med Allied Sci 2000, 55:37-66.
2. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:204S-33S.
3. Mann KG. The challenge of regulating anticoagulant drugs: focus on warfarin. Am Heart J 2005, 149:S36-42.
4. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:188S-203S.
5. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997, 337:688-98.
6. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004, 140:867-73.
7. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010, 121:1523-32.
8. Orfeo T, Butenas S, Brummel-Ziedins KE, Mann KG. The tissue factor requirement in blood coagulation. J Biol Chem 2005, 280:42887-96.
9. Orfeo T, Brummel-Ziedins KE, Gissel M, Butenas S, Mann KG. The nature of the stable blood clot procoagulant activities. J Biol Chem 2008, 283:9776-86.
10. Jenny R, Church W, Odegaard B, Litwiller R, Mann K. Purification of six human vitamin K-dependent proteins in a single chromatographic step using immunoaffinity columns. Prep Biochem 1986, 16:227-45.
11. Brummel-Ziedins K, Vossen CY, Rosendaal FR, Umezaki K, Mann KG. The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost 2005, 3:1472-81.
12. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992, 267:12528-38.
13. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003, 1:1258-63.
14. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001, 97:2308-13.
15. Bedsted T, Swanson R, Chuang YJ, Bock PE, Bjork I, Olson ST. Heparin and calcium ions dramatically enhance antithrombin reactivity with factor IXa by generating new interaction exosites. Biochemistry 2003, 42:8143-52.
16. Cote HC, Bajzar L, Stevens WK, Samis JA, Morser J, MacGillivray RT, Nesheim ME. Functional characterization of recombinant human meizothrombin and Meizothrombin(desF1). Thrombomodulin-dependent activation of protein C and thrombin-activatable fibrinolysis inhibitor (TAFI), platelet aggregation, antithrombin-III inhibition. J Biol Chem 1997, 272:6194-200.
17. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005, 3:514-21.
18. Holmes MB, Schneider DJ, Hayes MG, Sobel BE, Mann KG. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation 2000, 102:2051-7.
19. Butenas S, Branda RF, van't VeerC, Cawthern KM, Mann KG. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001, 86:660-7.
20. Klaeffling C, Piechottka G, Brevern GDV, Mosch G, Mani H, Luxembourg B, Lindhoff-Last E. Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium. Ther Drug Monit 2006, 28:375-81.
21. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007, 47:218-26.
22. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation 2001, 104:2311-7.
23. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kalebo P. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006, 4:121-8.
24. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muelhofer E, Misselwitz F, Eriksson BI. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008, 100:453-61.
25. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin. J Clin Pharmacol 2006, 46:981-90.
26. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008, 112:2242-7.
27. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin- antithrombin III but is susceptible to inactivation by antithrombin III- independent inhibitors. J Clin Invest 1990, 86:385-91.
28. Francis CW, Markham RE, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983, 102:220-30.
29. Kumar R, Beguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. Thromb Haemost 1995, 74:962-8.
30. McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol 1996, 16:1285-91.
31. Thomas DP, Merton RE, Gray E, Barrowcliffe TW. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin, and a pentasaccharide fragment in an animal model. Thromb Haemost 1989, 61:204-7.